Immune activation, apoptosis, and treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy

AIDS

Volumn 24, Issue 13, 2010, Pages 1991-2000

  Piconi, Stefania ^a   Trabattoni, Daria ^c   Gori, Andrea ^b   Parisotto, Serena ^c   Magni, Carlo ^a   Meraviglia, Paola ^a   Bandera, Alessandra ^b   Capetti, Amedeo ^a   Rizzardini, Giuliano ^a   Clerici, Mario ^a,c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b University Hospital   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

antiretroviral therapy; CD4 + T lymphocytes; cytokines; HIV; immune activation; immunological nonresponders; lipopolysaccharide; PD L1; PD1; toll like receptor; Treg cells

Indexed keywords

CASPASE 8; CASPASE 9; GAG PROTEIN; INTERLEUKIN 10; KI 67 ANTIGEN; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL STIMULATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE DURATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; VIREMIA;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 77955432632     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833c93ce     Document Type: Article

References (54)

1. Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000; 14:1955-1960.
2. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-1756.
3. Viard JP, Mocroft A, Chiesi A, Kirk O, Røge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active anti-retroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294.
4. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 183:1534-1543.
5. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
6. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
7. Al-Harthi L, Voris J, Du W, Wright D, Nowicki M, Frederick T, et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006; 193:1202-1210.
8. Renaud M, Katlama C, Mallet A, Calvez V, Carcelain G, Tubiana R, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-676.
9. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St. Clair M, et al. Immunrecostitution in the first year of potent antiretroviral therapy and its relationship with virologic response. J Infect Dis 2000; 181:358-363.
10. Yadavalli G, Lederman M, Lisgaris M, Stevens W, Sanne I, Cahn P, et al. South African patients have decreased CD4R T cell replenishment and persistently elevated T cell activation during HAART compared with North American patients, despite better virologic responses [Abstract]. Conf Retrovir Opportunistic Infect. 2006; 13: abstract no 313.
11. Lederman MM, McKinis R, Kelleher D, Cutrell A, Mellors J, Neisler M, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14:2635-3264.
12. Kalayjian RC, Landay A, Pollard RB, Taub DD, Gross BH, Francis IR, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8R cell depletion, reduced expression of CD28 on CD8R cells, and reduced thymic volumes. J Infect Dis 2003; 187:1924-1933.
13. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, et al. Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretro-viral therapy in HIV-1 positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-434.
14. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
15. 3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
16. Kelley CF, Kitchen CMR, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4R cell count restoration in HIV-infected patients receiving long-term anti-retroviral treatment. Clin Infect Dis 2009; 48:787-794.
17. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600.
18. French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitu-tion of CD4R T cells. J Infect Dis 2009; 200:1212-1215.
19. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial traslocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
20. Ciccone EJ, Read SW, MannonPJ, Yao MD, Hodge JN, Dewar R, et al. Cycling of gut mucosal CD4R T cells decreases after prolonged antiretroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 2010; 3:172-181.
21. Hofer U, Speck RF. Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection. Semin Immunopathol 2009; 31:257-266.
22. Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, Piacentini L, et al. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther 2009; 14:321-330.
23. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 2008; 3:356-361.
24. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Man DL, et al. Interleukin-2 production used to detect antigenic peptide recognition of HIV synthetic peptides recognition by T helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989; 339:383-386.
25. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
26. Complications and side effects. The DAD study: a large European database looks at heart attacks. TreatmentUpdate. 2009; 21:11
27. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
28. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
29. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.
30. Baker J, Peng G, Rapkin J, Abrams D, Silverberg M, Cavert W, et al. HIV-related immune suppression after ART predicts risk of nonopportunistic diseases: results from the FIRST study. Conf Retrovir Opportunistic Infect. 2007; 37
31. Iser DM, Lewin SR. The pathogenesis of liver disease in the setting of HIV-hepatitis virus B coinfection. Antivir Ther 2009; 14:155-164.
32. Kirk JB, Bidwell GoetzM.Human immunodeficiency virusinan aging population, a complication of success. J Am Geriatr Soc 2009; 57:2129-2138.
33. Cary RR, Gupta G, Zeytun A, van Velkinburgh JC, Pardington PE. Pathogen-specific innate immune response. Adv Exp Med Biol 2007; 598:342-357.
34. Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006; 72:1102-1113.
35. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007; 15:114-117.
36. Miller Sanders C, Cruse JM, Lewis RE. Toll-like receptor and chemokine receptor expression in HIV-infected T lymphocyte subsets. Exp Mol Pathol 2009; 75:126-138.
37. Denning TL, Wang Y, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007; 8:1086-1094.
38. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 11:235-238.
39. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21:1105-1111.
40. Cao W, Jamieson BD, Hultin LE, Hultin PM, Detels R. Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses 2009; 25:183-191.
41. Bi X, Suzuki Y, Gatanaga H, Oka S. High frequency and proliferation of CD4R FOXP3R Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol 2009; 39:301-309.
42. Terzieva V, Popova D, Kicheva M, Todorova Y, Markova R, Martinova F, et al. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4RCD25R T regulatory cells in HIV-1 infected persons under HAART. Int Immunopharmacol 2009; 9:831-836.
43. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(R)CD25(R)FOXP3(R) regulatory T cells. J Infect Dis 2009; 199:1318-1322.
44. Jiao Y, Fu J, Xing S, Fu B, Zhang Z, Shi M, et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8R T cells in HIV-1-infected typical progres-sors, but not in long-term nonprogressors. Immunology 2009; 128 (1 Suppl):e366-e375.
45. Kared H, Lelièvre JD, Donkova-Petrini V, Aouba A, Melica G, Balbo M, et al. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 2008; 22:2451-2460.
46. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
47. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharied. J Exp Med 2003; 197:403-411.
48. Dai J, Liu B, Li Z. Regulatory T cells and toll-like receptors: what is the missing link? Int Immunopharmacol 2009; 9:528-533.
49. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thompson AW. Regulated compartimentalization of programmed cell death-1 discriminates CD4RCD25R resting regulatory T cells from activated T cells. J Immunol 2006; 176:2808-2816.
50. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003; 101:2514-2520.
51. Askenasy N, Kaminitz A, Yarkoni S. Mechanism of T regulatory cell function. Autoimmun Rev 2008; 7:370-375.
52. Venkatachari NJ, Buchanan WG, Ayyavoo V. Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo. Virology 2008; 376:140-153.
53. R T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007; 179:1979-1987.
54. Vignali DAA, Collison LW, Woorkman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523-532.